Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

NCT01961063 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01961063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01961063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 31, 2015
Completion date
July 6, 2027
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related non-hodgkin lymphoma, aids-related plasmablastic lymphoma, aids-related primary effusion lymphoma, hiv infection